Economic assessment of hepatitis C treatments;Evaluation medico-economique des prises en charge therapeutiques des malades infectes par le virus de l'hepatite C

Gastroenterologie Clinique et Biologique

Volumn 24, Issue 11, 2000, Pages 1047-1051

  Loubière, Sandrine ^a   Rotily, Michel ^a,b   Moatti, Jean Paul ^a  

^a INSERM   (France)

^b OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

Author keywords

Cost benefit analysis; Cost effectiveness analysis; Decision analysis; Hepatitis C virus; Quality of life; Treatment

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT;

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE POLICY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MEDICAL DECISION MAKING; QUALITY OF LIFE; COMPARATIVE STUDY; COST OF ILLNESS; ECONOMICS; REVIEW; TIME;

ANTIVIRAL AGENTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; QUALITY OF LIFE; TIME FACTORS;

EID: 0034330597     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Estimation du nombre de sujets infectes par le VHC en France, 1994-95
2. Seroprevalence et facteurs de risque de l'hepatite C dans un echantillon national de volontaires a un examen de sante de la securite sociale
3. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy
4. Randomised trial of interferon α-2b plus ribavirin for 48 weeks for treatment of chronic hepatitis C virus
5. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C
6. Cost-effectiveness of treatment for chronic hepatitis C
7. Management of hepatitis C: Current and future perspectives
8. Efficience comparee de trois strategies de prise en charge de l'hepatite chronique C: Influence sur le risque de cirrhose a 8 ans
9. Analyse cout-efficacite du traitement de l'hepatite chronique C
10. The cost-effectiveness of alpha interferon in the treatment of chronic active hepatitis C
11. Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal
12. Estimates of the cost-effectiveness of a single course of interferon alpha-2b in patients with histologically mild chronic hepatitis C
13. Cost-effectiveness of 6 and 12-months of interferon-α treatment for chronic hepatitis C
14. Pretreatment evaluation of chronic hepatitis C: Risks, benefits and costs
15. EASL International Consensus Conference on Hepatitis C Paris, February 26-28, 1999, Consensus Statement. European Association for the Study of the Liver
16. Long-term mortality after transfusion-associated non-A, non-B hepatitis
17. Clinical outcomes after transfussion-associated hepatitis C
18. Decision roles of cost-effectiveness analysis
19. On the (near) equivalence of cost-effectiveness and cost-benefit analyses
20. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: A meta-analysis of diagnosis test characteristics
21. Natural history of liver fibrosis progression in patients with chronic hepatitis C: The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups
22. Qaly or not Qalys: That is the question?
23. Hepatite C et qualite de vie